CLINICAL ASPECTS OF INTERFERONS NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


CLINICAL ASPECTS OF INTERFERONS

Dev Med Virol; 4:1-366 1988. Unique Identifier : AIDSLINE ICDB/89649846
Anonymous; No affiliation given

Abstract: Clinical applications of interferons (IFNs) in infectious and immune diseases, clinical applications of IFNs in cancer, and biological properties of IFNs as shown by experimental systems are reviewed. The following topics are covered: intranasal IFNs for control of respiratory viral infections; IFN therapy of herpes simplex dermal infections and papillomavirus condylomata; IFN therapy in acute viral illnesses; the role of IFNs in the treatment of Kaposi's sarcoma and AIDS; IFN in the treatment of subacute sclerosing panencephalitis; clinical trials with IFNs in multiple sclerosis; the promise of IFN therapy in parasitic diseases; IFN treatment of non-Hodgkin's lymphoma and myeloma; the role of IFN-alpha in the treatment of hairy cell leukemia; clinical studies of alpha and gamma IFNs in chronic myelogenous leukemia; IFN therapy of chronic lymphocytic leukemia and viral infections in leukemia patients; IFNs in the treatment of metastatic renal cell carcinoma; IFNs in breast cancer; osteosarcoma management and IFN; clinical use of IFNs in the treatment of malignant brain tumors; IFN treatment of neuroendocrine tumors of the pancreas and gut; the role of beta IFN in the treatment of cervical dysplasia; IFNs in combination with cytotoxic modalities for cancer treatment; toxic effects; pharmacokinetics and practical implications; monitoring of IFN therapy by assay of IFN-induced (2'-5') oligo A synthetase in human peripheral WBCs; IFN studies in nonhuman primates; animal model systems to evaluate the antitumor activity of IFNs; effects of polynucleotides on monkeys and man; the potential for specific targeting of lymphokines as indicated by delivery of IFNs to target cells using monoclonal antibodies; immunomodulatory actions of IFNs; and synergistic actions of IFNs and tumor necrosis factor.
Keywords: Animal Human Interferons/*THERAPEUTIC USE Neoplasms/*THERAPY MONOGRAPH

KWDanimalhumaninterferons/KWDtherapeuticuseneoplasms/KWDtherapymonograph
890430
M8940672

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .